| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Alanyltyrosine does not have a well-defined pharmacological target. As a dipeptide metabolite, it is involved in protein metabolism and amino acid transport. The compound may affect the release of anabolic hormones and the availability of fuel for activity. It is considered a favorable synergistic food ingredient. Its biological activities are related to its role as a nutrient and metabolite.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro, alanyltyrosine is used as a research tool to study amino acid metabolism and peptide transport. As a dipeptide, it can be transported into cells via peptide transporters (PEPT1 and PEPT2). The compound is metabolized to its constituent amino acids, alanine and tyrosine, which have various metabolic functions. Its in vitro activities are primarily related to its role as a nutrient and metabolite. |
| ln Vivo |
In vivo, alanyltyrosine is an incomplete breakdown product of protein digestion or protein catabolism. It is a metabolite that is functionally related to L-alanine and L-tyrosine. The compound may affect the release of anabolic hormones, the availability of fuel for activity, and the prevention of muscular damage brought on by exertion. It is considered a favorable synergistic food ingredient.
|
| Enzyme Assay |
General protocols for the study of alanyltyrosine as a metabolite use analytical chemistry methods. The compound is extracted from biological samples (plasma, urine, tissues) using protein precipitation or solid-phase extraction. The extracted samples are analyzed by HPLC with UV or fluorescence detection, or by LC-MS/MS. The concentration of alanyltyrosine is quantified using external or internal standards. The compound's role in protein metabolism and amino acid transport is studied using cell culture models.
|
| Cell Assay |
General protocols for cell-based studies of alanyltyrosine use intestinal epithelial cells (e.g., Caco-2) or other cell lines expressing peptide transporters. Cells are seeded in transwell plates and allowed to form monolayers. Alanyltyrosine is added to the apical or basolateral compartment, and its transport across the monolayer is measured by HPLC or LC-MS. The effects of inhibitors or modulators of peptide transporters are studied. The compound's metabolism to alanine and tyrosine is also investigated.
|
| Animal Protocol |
General protocols for in vivo studies of alanyltyrosine use animal models to study protein metabolism and amino acid absorption. The compound is administered orally or intravenously, and blood samples are collected at various time points. The concentration of alanyltyrosine and its constituent amino acids (alanine, tyrosine) in plasma is measured by HPLC or LC-MS. The compound's bioavailability, metabolism, and elimination are characterized. Its effects on hormone release and muscle recovery are also investigated in exercise models.
|
| ADME/Pharmacokinetics |
Alanyltyrosine has a molecular weight of 252.27 g/mol (C12H16N2O4). It is a dipeptide composed of alanine and tyrosine. As a peptide, it is susceptible to proteolytic degradation in the gastrointestinal tract and bloodstream. It is transported into cells via peptide transporters. Its pharmacokinetic properties are typical of small peptides, with rapid absorption and metabolism.
|
| Toxicity/Toxicokinetics |
The toxicity profile of alanyltyrosine is favorable as a naturally occurring dipeptide and metabolite. It is generally recognized as safe as a food ingredient. At high doses, it may cause gastrointestinal discomfort. The compound is well tolerated and has no significant toxicity. Comprehensive toxicological studies are not required for naturally occurring amino acid derivatives.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Ala-Tyr is a dipeptide composed of L-alanine and L-tyrosine linked by a peptide bond. It is a metabolite functionally related to L-alanine and L-tyrosine. Ala-Tyr has been reported in Trypanosoma brevicornu, and relevant data are available for reference.
Alanyltyrosine (CAS 3061-88-9) is a dipeptide composed of L-alanine and L-tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism and has a role as a metabolite. The compound is functionally related to L-alanine and L-tyrosine. It is used in research on amino acid metabolism, nutrition, and peptide transport. It has no approved therapeutic indications and is not a pharmaceutical drug. |
| Molecular Formula |
C12H16N2O4
|
|---|---|
| Molecular Weight |
252.26644
|
| Exact Mass |
252.111
|
| CAS # |
3061-88-9
|
| PubChem CID |
92946
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
558.0±50.0 °C at 760 mmHg
|
| Melting Point |
238-240℃ (decomposition)
|
| Flash Point |
291.2±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
-0.05
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
18
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@H](N)C(N[C@H](C(O)=O)CC1=CC=C(O)C=C1)=O
|
| InChi Key |
ALZVPLKYDKJKQU-XVKPBYJWSA-N
|
| InChi Code |
InChI=1S/C12H16N2O4/c1-7(13)11(16)14-10(12(17)18)6-8-2-4-9(15)5-3-8/h2-5,7,10,15H,6,13H2,1H3,(H,14,16)(H,17,18)/t7-,10-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~4 mg/mL (~15.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9640 mL | 19.8200 mL | 39.6401 mL | |
| 5 mM | 0.7928 mL | 3.9640 mL | 7.9280 mL | |
| 10 mM | 0.3964 mL | 1.9820 mL | 3.9640 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03246659 | COMPLETED | Drug: 111In-CP04 Drug: 111In-CP04 with co-administration of gelofusine/gelaspan |
Medullary Thyroid Carcinoma | Paola Anna Erba | 2016-08 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
